Trade

with

Nymox Pharmaceutical Corp
(NASDAQ: NYMX)
AdChoices
5.31
+0.11
+2.12%
After Hours :
4.41
-0.90
-16.95%

Open

5.25

Previous Close

5.20

Volume (Avg)

88.09k (92.66k)

Day's Range

5.09-5.37

52Wk Range

3.81-7.89

Market Cap.

184.09M

Dividend Rate ( Yield )

-

Beta

0.70

Shares Outstanding

35.40M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 3.36M

    • Net Income

    • -4.91M

    • Market Cap.

    • 184.09M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -181.65

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.70

    • Forward P/E

    • -

    • Price/Sales

    • 58.14

    • Price/Book Value

    • -30.49

    • Price/Cash flow

    • -27.17

      • EBITDA

      • -4.89M

      • Return on Capital %

      • -535.20

      • Return on Equity %

      • -

      • Return on Assets %

      • -535.20

      • Book Value/Share

      • -0.17

      • Shares Outstanding

      • 35.40M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -10.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 50.96

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 88.00

            • 82.75

            • Pre-Tax Margin

            • -181.65

            • 39.38

            • Net Profit Margin

            • -181.65

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 72.60

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -588.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 0.16

              • 2.92

              • Quick Ratio

              • 0.14

              • 2.35

              • Interest Coverage

              • -101.58

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.17

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -29.50

                • 238.10

                • P/E Ratio 5-Year High

                • -59.62

                • 634.30

                • P/E Ratio 5-Year Low

                • -15.92

                • 124.82

                • Price/Sales Ratio

                • 53.48

                • 8.94

                • Price/Book Value

                • -28.09

                • 8.12

                • Price/Cash Flow Ratio

                • -27.17

                • 47.85

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -535.20

                        (-188.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 9.27

                      • 1.48

                      • Asset Turnover

                      • 2.95

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -4.88M
                      Operating Margin
                      -145.43
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -27.17
                      Ownership

                      Institutional Ownership

                      4.84%

                      Top 10 Institutions

                      3.77%

                      Mutual Fund Ownership

                      1.33%

                      Float

                      65.09%

                      5% / Insider Ownership

                      -

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Global Opportunities

                      •  

                        225,000

                      • 0.00

                      • 0.64

                      • LoCorr Long/Short Equity Fund

                      •  

                        193,300

                      • 0.00

                      • 0.55

                      • CONSALVE Global Top 20 Fund

                      •  

                        20,000

                      • 0.00

                      • 0.06

                      • Fidelity® NASDAQ Composite Index® Fund

                      •  

                        5,184

                      • 62.61

                      • 0.01

                      • SPDR® S&P International Small Cap ETF

                      •  

                        4,720

                      • 0.00

                      • 0.02

                      • Fidelity® Nasdaq Composite Tr Stk Fund

                      •  

                        1,794

                      • 9.52

                      • 0.01

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Advisors Asset Management

                      •  

                        339,888

                      • +341.04%

                      • 0.97

                      • Winkler-Invest

                      •  

                        225,000

                      • 0.00%

                      • 0.64

                      • LoCorr Fund Management, LLC

                      •  

                        193,300

                      • 0.00%

                      • 0.55

                      • Canada Pension Plan Investment Board

                      •  

                        120,913

                      • 0.00%

                      • 0.34

                      • Wms Partners, LLC

                      •  

                        64,662

                      • +2.07%

                      • 0.18

                      • Marathon Capital Management LLC

                      •  

                        30,000

                      • -23.27%

                      • 0.09

                      • Renaissance Technologies Corp

                      •  

                        28,000

                      • +5.64%

                      • 0.08

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Nymox Pharmaceutical Corp was incorporated under the Canada Business Corporations Act in May 1995. The Company is a biopharmaceutical corporation engaged in research and development of diagnostics and drugs for brain disorders and di...moreseases of the aged with an emphasis on Alzheimer’s disease. It has three proprietary products on the market, and a significant R&D pipeline of products in development for the treatment of such conditions and diseases as BPH, prostate cancer, Alzheimer’s disease or AD, E. coli O157; H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. The Company's products include: NicAl...moreert, TobacAlert and AlzheimAlert. The Company has developed and markets NicAlert and TobacAlert, test strips for determining whether a person is using tobacco products or has been recently exposed to second-hand smoke. It has also developed AlzheimAlert, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer’s disease. The Company is also developing NX-1207, treatments for BPH and prostate and liver cancer. It is also developing NXC-4720, novel antibacterial agents for the treatment of E. coli O157 bacterial contamination in meat and other food and drink products. Its AlzheimAlert test is certified with a CE Mark, making the device eligible for sale in the European Union. The Company's competitors include: Eli Lilly and Company, GE Healthcare, Athena Diagnostics, Inc., Fujirebio Europe NV, Amorfix Life Sciences Ltd, LabCorp, Quest Diagnostics, OraSure Technologies Inc., Abraxis LLC, Roche Diagnostics, Abbott and Diagnostic Products Corporation.lessless

                      Key People

                      Dr. Paul Averback,M.D.,D.A.B.P.

                      Founder/Chairman of the Board/President/Director

                      Mr. Andre Monette

                      CFO/Secretary/Treasurer

                      Jack Gemmell

                      Director/Chief Information Officer/General Counsel

                      Dr. Roger Guy,M.D.

                      Director

                      ProfessorDr. David Morse,PhD

                      Director

                      • Nymox Pharmaceutical Corp

                      • 9900 Cavendish Boulevard

                      • St. Laurent, QC H4M 2V2

                      • CAN.Map

                      • Phone: +1 800 936-9669

                      • Fax: +1 514 332-2227

                      • nymox.com

                      Incorporated

                      1995

                      Employees

                      26

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: